Nicole Kucine, M.D., MS

Pediatric Hematology-Oncology
Nicole Kucine

My clinical interests include working with children with various blood disorders, such as sickle cell anemia, blood clotting disorders, and rare disorders called Myeloproliferative Neoplasms. I find it a privilege to be able to help families deal with their children's complex medical issues. By combining excellent, compassionate medical care with research aimed at improving outcomes and preventing disease-associated complications, I believe that we can make a difference for children with cancer and blood disorders.

After completing her Bachelor of Arts (BA) at Wellesley College, Dr. Nicole Kucine relocated to New York City where she received her medical degree (MD) from , State University of New York Health Science Center at Brooklyn (now the State University of New York-Downstate Medical Center). She completed her residency in Pediatrics at Robert Wood Johnson University Hospital in New Jersey in 2006 and served as Chief Resident from 2006-2007.

After residency, Dr. Kucine completed a fellowship in Pediatric Hematology/Oncology at the combined program of New York Hospital-Cornell University Medical College and the Memorial Sloan-Kettering Cancer Center (MSKCC). At MSKCC, she served as Special Fellow, looking at new therapeutic agents for high-risk acute lymphoblastic leukemia (ALL.)

At Weill Cornell, Dr. Kucine's research is focused in 2 areas: 1) a rare group of bone marrow disorders called Myeloproliferative Neoplasms (MPN), and 2) blood clotting disorders.  She looks forward to helping patients with a variety of hematologic medical concerns.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Oxford Health Plans [Liberty]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care [Medicare]
  • United Health Care


1. Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL. Efficacy of JAK2 Inhibitor INC16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.  Blood 2010 April 8; 115(14):2919-27.    

2. Lluis Espinosa, Severein Cathelin, Teresa D’Altri, Thomas Trimarchi, Alexander Statnikov, JOrdi Guiu, Veronica Rodilla, Julia Ingle’s-Esteve, Joseph Nomedeu, Beatriz Bellosillo, Carles Besses, Omar Abdel-Wahab, Nicole Kucine, Shao-Cong Sun, Guangchan Song, Charles C. Mullighan, Ross L. Levine, Klaus Rajewsky, Iannis Aifantis, and Anna Bigas.  The Notch/Hes1 Pathway Sustains NF-kB Activation through CYLD Repression in T Cell Leukemia.  Cancer Cell 2010 September 14;18(3):268-81.

3. Kucine N, Levine RL. JAK inhibitors and other novel agents in myeloproliferative neoplasms: are we hitting the target?  Therapeutic Advances in Hematology, 2011;2:203-11.

4. Francis JH, Gobin YP, Nagiel A, Dunkel IJ, Kucine N, Marr BP, Brodie SE, Abramson DH.  Thrombophilia in patients with retinoblastoma receiving ophthalmic artery chemosurgery.  Arch Opthalmol 2012 December 1;130(12):1605-8.

5. Kucine N, Chastain KM, Mahler M, Bussel JB. Primary Thrombocytosis in Children.  Haematologica, 2014;99(4):620-8.


Honors and Awards

Excellence in Teaching Award, Pediatric Clerkship, 2014

KL2 Scholars award, CTSC/NIH, 2012-2014